Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.67 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TACR2 | P21452 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.51 |
| ▸ | TUBB | P07437 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8983142 | 0.95 | NPC1 (0.65) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL2699064 | 0.94 | ALDH1A1 (0.66) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL7784719 | 0.94 | PDCD1 (0.74) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL2463491 | 0.90 | NPC1 (0.63) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL4241206 | 0.90 | TACR2 (0.74) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL2556112 | 0.89 | TACR2 (0.76) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL12335182 | 0.88 | TACR2 (0.60) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL22160281 | 0.87 | NPC1 (0.62) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL24707029 | 0.87 | NPC1 (0.55) | PDCD1CD274NPC1RAB9ATDP1 | |
| SCHEMBL752160 | 0.87 | ALDH1A1 (0.65) | PDCD1CD274NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347576-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS | UNIV HASSELT (BE) | 2025-04-23 | — | — | EP | disclosed |
| US-20240279183-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS | UNIVERSITEIT MAASTRICHT (NL) | 2024-08-22 | — | — | US | disclosed |
| EP-4347576-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS | Universiteit Hasselt (BE) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022253959-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS | UNIVERSITEIT HASSELT (BE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253959-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS | UNIVERSITEIT HASSELT (BE) | 2022-12-08 | — | — | WO | disclosed |
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-07 | — | — | US | disclosed |
| EP-3292127-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177690-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-8410116-B2 | Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-04-02 | — | — | US | disclosed |
| US-8410116-B2 | Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-04-02 | — | — | US | disclosed |
| US-20100190803-A1 | BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-29 | — | — | US | disclosed |
| US-20100190803-A1 | BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155344-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | TPH1, TPH2, HTR1B | PDCD1 4799/4885CD274 4820/4885NPC1 1008/4885 |
| US-20240279183-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS | MAG, GAP43, PMP22 | PDCD1 3402/4885CD274 3561/4885NPC1 171/4885 |
| US-20100190803-A1 | BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT | PSEN1, APP, BACE1 | PDCD1 2753/4885CD274 3291/4885NPC1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.